Skip to NavigationSkip to content


Moderna Therapeutics names Dr John Medlein as new President, Corporate and Product Strategy

Published on: 04/01/18

Messenger RNA (mRNA) therapeutics and vaccines specialist Moderna Therapeutics has announced the appointment of current board member Dr John Medlein as its new President of Corporate and Product Strategy, where he will manage a range of responsibilities including product advancement and strategy, partnering and product protection, and corporate strategy.

AstraZeneca strikes mRNA-based partnership in respiratory disease

AstraZeneca and MedImmune, the company’s biologics research arm, have forged a five year research partnership with mRNA-based pulmonary disease specialist Ethris to leverage the latter’s proprietary SNIM RNA technology in the development of stabilised non-immunogenic modified RNA therapies for respiratory diseases.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches